Skip to content

A clinical study on the effect of ultra-protective lung ventilation strategy on pulmonary ventilation and perfusion in patients with VV-ECMO

A clinical study on the effect of ultra-protective lung ventilation strategy on pulmonary ventilation and perfusion in patients with VV-ECMO - A clinical study on the effect of ultra-protective lung ventilation strategy on pulmonary ventilation and perfusion in patients with VV-ECMO

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095840
Enrollment
Unknown
Registered
2025-01-14
Start date
2025-01-15
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Interventions

General protective lung ventilation group:The general protective lung ventilation strategy was used to meet the tidal volume of 6-8 ml/kg and the predicted body weight
plateau pressure is 25-30 cmH2O
driving pressure is less than or equal to 15 cmH2O.
Ultra-protective lung ventilation group:The ultra-protective lung ventilation strategy was used to meet the tidal volume less than or equal to 4 ml/kg and the predicted body weight
plateau pressure is less than or equal to 25 cmH2O

Sponsors

The Second Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients with moderate and severe ARDS(PaO2/FiO2?200mmHg) who were treated with ECMO and mechanical ventilation at the same time; (2) Age >= 18 years old; (3) Body mass index <= 35kg/m^2.

Exclusion criteria

Exclusion criteria: (1) Contraindications of EIT monitoring, such as unstable spinal or pelvic fractures, pacemaker installation, automatic implantable cardiac defibrillator, skin lesions between the fourth and fifth ribs, etc. (2) Pregnancy; (3) Severe respiratory acidosis; (4) Hemodynamic instability or restlessness; (5) Central venous catheterization is located in femoral vein; (6) Refusing to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Ventilation blood flow ratio;Shunt rate;Dead space rate;Region of interest;End expiratory lung impedance;

Secondary

MeasureTime frame
Plateau pressure;Peak airway pressure;Lung compliance;Positive end-expiratory pressure;

Countries

China

Contacts

Public ContactJunbo Zheng

The Second Affiliated Hospital of Harbin Medical University

icuzhengjunbo@hrbmu.edu.cn+86 186 8678 1984

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026